US Patent 8,591,941: Scope, Claim Construction, Expiration, and Amphetamine Transdermal Patent Landscape

US Patent 8,591,941 protects a specific amphetamine transdermal patch architecture. Its core combination is an acrylic pressure-sensitive adhesive containing amphetamine, paired with a polyester/polyurethane multilayer backing. The patent does not claim amphetamine itself, all amphetamine patches, or every transdermal delivery system. Its practical value is concentrated in products using the claimed adhesive chemistry and backing-film construction, including products developed from the Noven transdermal amphetamine platform.

What does US Patent 8,591,941 claim?

The patent contains three principal claim categories:

Product claims covering an amphetamine-containing transdermal patch.
Method-of-use claims covering transdermal administration.
Manufacturing claims covering solvent mixing, casting, drying, and release-liner application.

The independent claims are claims 1, 10, 12, 14, and 15. Claims 2-9, 11, and 13 are dependent claims.

Claim	Claim type	Main limitation
1	Product	Acrylic pressure-sensitive adhesive, amphetamine, and polyester/polyurethane backing
10	Product	Non-functional acrylic plus amide-functional acrylic, amphetamine, and polyester/polyurethane backing
12	Product	Substantially the same architecture as claim 10
14	Method of use	Topical administration of the claim 1 device
15	Manufacturing method	Mixing, solvent casting, drying, and release-liner application

The patent is assigned to Noven Pharmaceuticals, Inc., the developer associated with the Xelstrym amphetamine transdermal system platform.[1]

What is the broadest enforceable scope of claim 1?

Claim 1 is the principal platform claim. It requires all of the following elements:

A transdermal drug delivery system.
Amphetamine as the drug.
A pressure-sensitive adhesive carrier layer.
An acrylic polymer in that carrier layer.
A therapeutically effective amount of amphetamine.
A backing layer adjacent to the carrier layer.
A backing structure consisting of polymeric polyester and polyurethane layers.

The claim does not require:

A particular amphetamine stereoisomer.
A specific percentage of amphetamine.
An amide-functional acrylic polymer.
A release liner.
A particular patch size.
A particular delivery rate.
A particular treatment indication.
A named commercial product.

This makes claim 1 materially broader than claims 10 and 12. A patch could fall within claim 1 without using the specific non-functional/acrylic-amide blend required by the narrower claims.

The principal limitation is the backing layer. A product using a single polyester film, a single polyurethane film, polyethylene, an occlusive laminate with different polymer layers, or a non-polymeric backing could avoid literal infringement of claim 1 if the structure does not contain the required polyester and polyurethane layers.

How do claims 10 and 12 narrow the patent?

Claims 10 and 12 require a more specific adhesive formulation:

A non-functional acrylic polymer.
An acrylic polymer containing amide functional groups.
Amphetamine.
A polyester/polyurethane polymeric backing.

The phrase "consisting essentially of" limits the carrier layer to the specified blend and ingredients that do not materially affect the basic and novel characteristics of the claimed system. The phrase is narrower than "comprising" but broader than "consisting of."

Claims 10 and 12 appear substantively duplicative based on the language supplied. Both require the same adhesive blend, amphetamine, and backing-layer construction. Claims 11 and 13 add a release liner to claims 10 and 12, respectively.

A competing patch that uses:

Only a non-functional acrylic polymer;
A silicone adhesive;
A polyisobutylene adhesive;
An acrylic polymer with a different functional group but no amide group; or
A different backing construction,

would have a stronger non-infringement position against claims 10 and 12 than against claim 1.

What formulation features are protected?

The formulation-related limitations fall into four groups.

Acrylic pressure-sensitive adhesive

The carrier layer is both the adhesive and the drug-containing matrix. The claim does not require a separate drug reservoir, membrane, gel, or rate-controlling layer. A matrix patch can therefore fall within the claim if the acrylic adhesive itself contains amphetamine.

Functional and non-functional acrylic polymers

Claim 2 introduces a blend of:

A non-functional acrylic polymer; and
An acrylic polymer containing functional groups.

Claim 3 limits the functional groups to amide groups. Claims 10 and 12 incorporate the amide-functional acrylic requirement directly into the independent product claims.

This formulation architecture may affect amphetamine solubility, crystallization, skin adhesion, drug loading, release characteristics, and manufacturing stability. The patent’s commercial value is therefore not limited to the presence of amphetamine. It also covers a specific adhesive-engineering approach.

Amphetamine concentration

Claims 5 and 6 specify amphetamine concentrations of:

About 0.5% to about 15% by weight of the carrier layer; and
About 15% by weight of the carrier layer.

The concentration limitation is measured against the weight of the carrier layer, not necessarily the total patch. A competing product with more than 15% amphetamine could avoid claims 5 and 6 while remaining exposed to claim 1 if all other elements are present.

The term "about" creates a potential claim-construction issue. Courts typically evaluate the term in the context of the specification, prosecution history, measurement precision, and technical tolerances.

Backing-layer construction

Claims 1, 10, and 12 require a backing layer made from polymeric layers consisting of:

A polyester layer; and
A polyurethane layer.

Claim 7 adds a thickness range of approximately 0.2 mm to 3 mm. Claim 8 adds a moisture vapor transmission rate of 10 to approximately 100 g/m²/24 hours.

Those limitations may be important in product comparison. A patch could use the same adhesive but avoid claims 7 and 8 through a different thickness or moisture vapor transmission rate. It could still remain exposed to claim 1 if the basic polyester/polyurethane backing combination is retained.

What do claims 14 and 15 protect?

Method-of-use claim 14

Claim 14 covers transdermal delivery of amphetamine by topically administering the claim 1 device to a subject in need.

The claim is dependent on the structure of claim 1. A method using an amphetamine patch that does not contain the claimed acrylic carrier and polyester/polyurethane backing would not literally meet claim 14.

Because the claim requires administration to a "subject in need thereof," its scope is directed to therapeutic use rather than unrestricted use of a patch. The claim does not specify:

Attention-deficit/hyperactivity disorder;
Narcolepsy;
A particular dosage;
A particular patch-wear period; or
A particular patient population.

Manufacturing claim 15

Claim 15 requires:

Uniformly mixing the specified acrylic polymers and amphetamine in a volatile solvent system.
Casting the carrier layer onto the polyester/polyurethane backing film.
Heating the cast layer to remove volatile solvents.
Applying a release liner.

The manufacturing claim is narrower than a general process claim for making an amphetamine patch. A manufacturer using hot-melt processing, solvent-free coating, a different drying process, or a different order of assembly may have a non-infringement position.

The claim may create manufacturing-process exposure even where a supplier or competitor attempts to modify product presentation without changing the final patch structure.

When does US Patent 8,591,941 expire?

The patent was granted on November 26, 2013.[1] Its application traces to a 2011 nonprovisional filing and an earlier 2010 priority filing. The ordinary 20-year patent-term calculation is tied to the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.

The base patent term is expected to reach approximately April 2031, subject to the official USPTO term calculation and any Orange Book-listed expiration date.[2] The patent should not be treated as expired merely because its 2010 priority filing is more than 20 years old. Provisional priority dates generally do not control the 20-year patent term.

Event	Date
Earliest disclosed priority	2010
Nonprovisional filing period	2011
Grant	November 26, 2013
Base-term horizon	Approximately April 2031
Patent-term adjustment	Must be confirmed from USPTO records
Patent-term extension	Must be confirmed from FDA and USPTO records

What is the FDA and Orange Book status associated with the patent?

Xelstrym, a d-amphetamine transdermal system, received FDA approval under NDA 214158 on June 2, 2022.[3] The product is manufactured by Noven Pharmaceuticals, Inc. and marketed as a transdermal system for the treatment of attention-deficit/hyperactivity disorder.

The FDA product labeling identifies Xelstrym as a d-amphetamine patch with multiple strengths. The product uses an acrylic adhesive matrix and a multilayer backing system, making the patent’s claim architecture commercially relevant to the approved product.[4]

An Orange Book listing determines whether a patent is formally submitted for an approved drug product and whether it may trigger a 30-month stay following a valid Paragraph IV notice. The existence of a patent, however, does not by itself establish an Orange Book listing. Orange Book status should be evaluated by:

NDA number;
Product strength;
Dosage form;
Patent-use code;
Listed patent expiration date; and
Current FDA publication status.

The supplied claims alone do not establish a current Orange Book listing, a patent-use code, or an approved-product patent-expiration entry. Those are regulatory-record questions governed by the FDA Orange Book database and the NDA file.[2]

Are there Paragraph IV challenges or generic-entry risks?

A Paragraph IV certification would be relevant to an ANDA applicant seeking approval before the expiration of a listed patent. For Xelstrym, the main possible generic-entry routes are:

A Paragraph IV challenge to the listed composition or device patent.
A Paragraph III certification with launch after patent expiration.
A non-infringement or invalidity position based on a redesigned patch.
A regulatory strategy relying on a different formulation or delivery architecture.

The most vulnerable claim features from a design-around perspective are the formulation and backing limitations. A generic manufacturer could attempt to use:

A different pressure-sensitive adhesive family;
An acrylic formulation without amide functional groups;
A different polymeric backing;
A backing with a different moisture vapor transmission rate;
A non-solvent manufacturing process; or
A different amphetamine concentration.

A Paragraph IV challenge could target anticipation, obviousness, indefiniteness, written description, enablement, or claim construction. The strongest potential validity issues would likely depend on prior art describing amphetamine in acrylic adhesive matrices and multilayer transdermal backings before the relevant filing date.

The claims are combination claims. Prior art would generally need to disclose, or render obvious, the combination of the amphetamine-loaded acrylic adhesive and the specified backing construction. Prior art showing only amphetamine patches, only acrylic adhesives, or only polyester/polyurethane laminates may not individually anticipate the full combination.

How strong is the patent estate for transdermal amphetamine?

The patent is strongest against products that reproduce the commercial architecture closely. Its coverage is narrower against products that change either the adhesive chemistry or the backing film.

Risk category	Assessment
Same acrylic matrix and same polyester/polyurethane backing	High
Same adhesive but different backing construction	Moderate to low under literal claim analysis
Amide-functional acrylic blend and same backing	High
Non-acrylic adhesive	Low
Same product architecture with different amphetamine loading	Potentially high under claim 1
Different manufacturing process	Product claims remain relevant; claim 15 may be avoided
Oral amphetamine generic	No direct infringement of these claims
Injectable amphetamine product	No direct infringement of these claims
Biosimilar competition	Not applicable because amphetamine is a small-molecule active ingredient

The patent does not create biosimilar risk because amphetamine is not a biologic. Competitive entry would occur through the ANDA pathway, an NDA for a reformulated product, or a 505(b)(2) application depending on the proposed product and regulatory strategy.[5]

What patent litigation and licensing issues affect the asset?

A patent document does not establish litigation, settlement, or licensing activity. Those issues require separate review of PACER, district-court dockets, PTAB proceedings, SEC filings, FDA records, and transaction disclosures.

For diligence purposes, the relevant questions are:

Whether Noven or an affiliated patent holder has sued an ANDA applicant.
Whether any defendant filed an inter partes review petition.
Whether a settlement includes a launch date, license, authorized-generic provision, or supply arrangement.
Whether the patent is licensed to a commercial partner.
Whether any terminal disclaimer links the patent to related Noven patents.
Whether the FDA Orange Book lists a method-of-use code that materially narrows approved-product coverage.

No biosimilar settlement analysis is applicable. Any competitive challenge would concern an ANDA or a reformulated amphetamine product.

How does US Patent 8,591,941 compare with competing patent strategies?

The patent uses a product-platform strategy rather than an indication-only strategy.

Patent strategy	Coverage focus	Commercial effect
US 8,591,941	Patch structure, adhesive chemistry, backing, manufacturing	Can reach the physical product and its manufacture
Method-of-use patent	Treatment of a defined condition or population	May be relevant to skinny-label generic entry
Formulation patent	Specific polymer blend, loading, or release profile	Can block close formulation copies
Device patent	Patch construction or delivery geometry	May cover competing physical devices
Manufacturing patent	Solvent casting and assembly process	More limited if competitors use an alternative process

US 8,591,941 has practical blocking value because claim 1 does not depend on a specific disease indication. Its main limitation is that it requires a particular patch construction. A competitor with a materially different adhesive or backing system may reduce infringement exposure while preserving transdermal amphetamine delivery.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

Launch after patent expiry, assuming no surviving related patents, regulatory exclusivity, or litigation judgment.
Earlier launch following a successful Paragraph IV challenge or settlement license.
Non-infringing launch using a redesigned adhesive/backing system under a separate regulatory application.

The third scenario is technically more difficult than a simple oral generic because the applicant must demonstrate adhesive performance, drug delivery, adhesion, irritation, residual drug, dose proportionality, and product quality. The regulatory burden can make formulation and manufacturing know-how commercially important even if a patent design-around is available.

Key Takeaways

US Patent 8,591,941 covers an amphetamine transdermal patch using an acrylic pressure-sensitive adhesive and a polyester/polyurethane multilayer backing.
Claim 1 is the broadest product claim and does not require an amide-functional acrylic blend or a release liner.
Claims 10 and 12 narrow the adhesive to a blend of non-functional and amide-functional acrylic polymers.
Claims 5-8 add concentration, thickness, and moisture vapor transmission limitations.
Claim 14 covers therapeutic administration of the claim 1 device.
Claim 15 covers a solvent-based mixing, casting, drying, and release-liner manufacturing process.
The patent is commercially relevant to the Xelstrym d-amphetamine transdermal system approved under NDA 214158.
The ordinary patent-term horizon is approximately April 2031, subject to USPTO patent-term adjustment and any applicable extensions.
The main design-around paths involve changing the acrylic adhesive chemistry, the backing-layer construction, or the manufacturing process.
Biosimilar competition is not relevant. Generic competition would proceed through an ANDA or, for a materially different product, an NDA or 505(b)(2) pathway.

FAQs about US Patent 8,591,941

Does the patent cover all d-amphetamine patches?

No. It covers patches containing amphetamine with the claimed acrylic adhesive and polyester/polyurethane backing structure.

Can a patch avoid infringement by using a silicone adhesive?

Potentially. A silicone adhesive would not literally satisfy the acrylic-polymer limitation, although the complete product and any equivalents analysis would require claim-by-claim review.

Does a different amphetamine dose avoid the patent?

Not necessarily. Claims 5 and 6 contain concentration limitations, but claim 1 does not specify a numerical concentration. A different dose could remain within claim 1 if the other structural limitations are present.

Is Xelstrym protected only by US Patent 8,591,941?

No. An approved transdermal product may be covered by multiple patents involving formulation, delivery performance, manufacturing, device construction, or methods of use. The complete Orange Book and patent-family record must be reviewed to determine the full estate.

Is the patent relevant to oral Adderall or Vyvanse generics?

No direct infringement follows from use of an oral amphetamine product. The patent is directed to a transdermal delivery system and related methods and manufacturing processes.

References

United States Patent and Trademark Office. (2013). Transdermal drug delivery system for amphetamine, U.S. Patent No. 8,591,941 B2. https://patents.google.com/patent/US8591941B2/en
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2022, June 2). FDA approves first amphetamine transdermal system for ADHD. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Xelstrym prescribing information. Noven Pharmaceuticals, Inc. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and patent certifications. https://www.fda.gov/drugs/development-resources/abbreviated-new-drug-application-anda/gi-drug-review-process-questions-and-answers-percent-iv-certifications-and-30-month-stays-percent-iv-disputes-anda-submission-and-approval

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	053309	⤷ Start Trial
Canada	2583340	⤷ Start Trial
European Patent Office	1807033	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,591,941

Summary for Patent: 8,591,941